1,632 results on '"Peyvandi F."'
Search Results
2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
3. Evaluation of procoagulant imbalance in Cushing’s syndrome after short- and long-term remission of disease
4. Lombardy diagnostic and therapeutic network of thrombotic microangiopathy
5. Reduced circulating FABP2 in patients with moderate to severe COVID-19 may indicate enterocyte functional change rather than cell death
6. PB0189 Knowledge and Attitudes of Haemophilic Patients Toward Gene Therapy
7. OC 42.2 Incidence and Risk Factors of Major Adverse Cardiovascular Events in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura during Remission
8. PB0624 A-SURE: Intra-Patient Comparison of Prophylactic Effectiveness of a Recombinant Factor VIII Fc Fusion Protein Versus Standard Half-Life Factor VIII in Hemophilia A
9. OC 24.3 Minimum Baseline FVIII Levels Required to Prevent Joint Bleeding Episodes: A Study in Mild Hemophilia A
10. BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1
11. PB0500 Edoxaban for Acute and Long-Term Treatment of Venous Thromboembolism: Real-Life Data from a Single Center Cohort Study
12. PB0313 Towards the Standardisation of ADAMTS-13 Antibody Testing in Thrombotic Thrombocytopenic Purpura (TTP)-Results of the IMATAS Collaborative Study
13. PB0333 Therapeutic Plasma Exchange-Related Complications in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
14. PB0191 myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry
15. A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC
16. OC 60.4 Joint Damage in Patients Affected by Von Willebrand Disease: A Single-Center Experience
17. OC 50.3 Inhibitor Development Upon Switch After 50 EDs from Plasma-Derived to Recombinant FVIII in Pups with Severe Haemophilia A: The PUP-SWITCH Study Results
18. PB0663 Risk Factors for Atherosclerosis in Patients with Hemophilia
19. LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A
20. PB0321 Prospective Evaluation of the HemosIL AcuStar ADAMTS13 Activity Assay
21. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1
22. OC 26.3 Main Features of Ischemic Stroke in Patients with Acute Immune-Mediated Thrombotic Thrombocytopenic Purpura
23. PB0683 Patients at Higher Risk of Spontaneous Joint Bleeding during Emicizumab Prophylaxis: A Study on Global Coagulation Assays and Arthropathy Scores
24. PB0640 Safety and Efficacy of Combined Dual Antiplatelet Therapy and FVIII Prophylaxis in Hemophilia A Patients after the Acute Coronary Syndrome
25. OC 69.5 Outcomes in Adult and Adolescent Patients with Severe Hemophilia a in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis from an Observational Study with Factor VIII Prophylaxis
26. OC 75.3 Phenotype and Genotype Characterization of Patients with Congenital Fibrinogen Deficiencies: A Retrospective Analysis of the PRO-RBDD Database
27. PB0316 Bortezomib for the Treatment of Multi-Refractory Immune-Mediated Thrombotic Thrombocytopenic Purpura: An Italian Multicenter Survey
28. OC 20.5 The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy
29. PB0844 Assessment of the De Novo Origin of the p.Val1316Met Mutation in Four Unrelated Patients with Type 2B von Willebrand Disease
30. OC 60.2 Population-Based Prevalence and Mutational Landscape of Von Willebrand Disease using Large-Scale Genetic Databases
31. PB1239 Prophylaxis with Extended Half-life Products in Patients with Hemophilia A: Real-life Data of the Milan Cohort
32. PB0027 Assessing Genetic Risk Factors for Early-Onset Coronary Artery Disease in Iranians
33. OC 52.2 Residual Burden of Liver Disease After HCV-Clearance in Hemophilia: AWord of Caution in the Era of Gene Therapy
34. PB0667 Development and Clinical Utility of Anti-Emicizumab Antibody Detection Assays
35. OC 42.3 Immune-Mediated TTP Patients in Remission with Recovered ADAMTS13 Activity but an Open ADAMTS13 Conformation are at Risk for Earlier ADAMTS13 Relapse
36. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
37. Hemostatic abnormalities in patients with Ehlers–Danlos syndrome
38. Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes
39. An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS‐VWF study
40. Recombinant factor XIII A‐subunit in a patient with factor XIII deficiency and recurrent pregnancy loss
41. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement
42. Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency
43. Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis
44. Minimal factor XIII activity level to prevent major spontaneous bleeds
45. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
46. Evolution of Haemophilia Care in Europe: 10 years of the principles of care
47. Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura
48. Pregnancy outcome after a first episode of cerebral vein thrombosis
49. Advances in the treatment of bleeding disorders
50. Liver health in patients with hemophilia: Residual risk factors of liver-related complications after HCV-clearance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.